Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than -2.5. However, the benefit of alendronate in women with ...

Alendronate sodium is a bisphosphonate used to treat Paget disease of bone (PDB). The approved dosage of 40 mg/day for 6 months is generally well tolerated, but esophageal irritation can occur if ...